Literature DB >> 21613799

Decreased RECK and Increased EMMPRIN expression in urothelial carcinoma of the bladder are associated with tumor aggressiveness.

Daniel Wittschieber1, Albrecht Stenzinger, Frederick Klauschen, Carsten Stephan, Klaus Jung, Andreas Erbersdobler, Anja Rabien.   

Abstract

OBJECTIVE: Urothelial bladder carcinomas show a divergent biological behavior, which significantly complicates risk stratification and clinical management. The MMP repressor RECK and the MMP activator EMMPRIN regulate the invasive potential by metalloproteinase-induced stromal degradation. Data on RECK in urothelial bladder cancer are lacking and information on EMMPRIN is sparse. This study aims to investigate the expression of RECK and EMMPRIN in urothelial carcinoma of the bladder and to correlate these findings with clinicopathological parameters.
METHODS: Our study included 127 specimens of urothelial carcinomas derived from 103 patients who underwent either TUR-B or cystectomy. Immunohistochemical expression analysis was performed for RECK, EMMPRIN, MMP-2, MMP-9 and MMP-14. Expression levels were graded for staining intensity and correlated with pT stage and WHO tumor grade.
RESULTS: Invasive (≥pT1) as well as WHO high-grade urothelial carcinomas showed a statistically significant and stepwise downregulation of RECK (p < 0.001) and concomitant upregulation of EMMPRIN (p < 0.001) compared to non-invasive and WHO low-grade tumors. No correlation was observed for the MMPs investigated.
CONCLUSION: Decreased RECK and increased EMMPRIN expression are associated with increasing stage and grade. Both proteins may serve as molecular marker for the distinction between potentially invasive (≥pT1) and non-invasive tumors (≤pTa).
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21613799     DOI: 10.1159/000323563

Source DB:  PubMed          Journal:  Pathobiology        ISSN: 1015-2008            Impact factor:   4.342


  6 in total

1.  Clinical significance of RECK promoter methylation in pancreatic ductal adenocarcinoma.

Authors:  Xiong-Xiong Lu; Shu-Min Zhang; Yuan Fang; Zheng-Ting Wang; Jun-Jie Xie; Qian Zhan; Xia-Xing Deng; Hao Chen; Jia-Bin Jin; Cheng-Hong Peng; Hong-Wei Li; Bai-Yong Shen
Journal:  Tumour Biol       Date:  2013-06-08

2.  Expression of extracellular matrix metalloproteinase inducer and fascin in urinary bladder cancer: Correlation with clinicopathological characteristics.

Authors:  Dalia Mohamed Abd El-Rehim; Nehad Mohamed Reda Abd El-Maqsoud; Amr Mohamed Abd El-Hamid; Tarek Khalaf Fath El-Bab; Ehab Mohamed Galal
Journal:  Mol Clin Oncol       Date:  2013-01-02

Review 3.  The biological function and clinical utilization of CD147 in human diseases: a review of the current scientific literature.

Authors:  Lijuan Xiong; Carl K Edwards; Lijun Zhou
Journal:  Int J Mol Sci       Date:  2014-09-29       Impact factor: 5.923

4.  Renal cell neoplasias: reversion-inducing cysteine-rich protein with Kazal motifs discriminates tumor subtypes, while extracellular matrix metalloproteinase inducer indicates prognosis.

Authors:  Anja Rabien; Carsten Stephan; Ergin Kilic; Wilko Weichert; Glen Kristiansen; Kurt Miller; Klaus Jung; Andreas Erbersdobler
Journal:  J Transl Med       Date:  2013-10-16       Impact factor: 5.531

5.  MiR-200c promotes bladder cancer cell migration and invasion by directly targeting RECK.

Authors:  Yidong Cheng; Xiaolei Zhang; Peng Li; Chengdi Yang; Jinyuan Tang; Xiaheng Deng; Xiao Yang; Jun Tao; Qiang Lu; Pengchao Li
Journal:  Onco Targets Ther       Date:  2016-08-16       Impact factor: 4.147

6.  CD147 as a novel biomarker for predicting the prognosis and clinicopathological features of bladder cancer: a meta-analysis.

Authors:  Hongru Li; Yadong Xu; Hui Li
Journal:  Oncotarget       Date:  2017-07-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.